Atomic Interactions and Profile of Small Molecules Disrupting Protein–Protein Interfaces: the TIMBAL Database
暂无分享,去创建一个
[1] P. Hajduk,et al. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. , 1997, Journal of medicinal chemistry.
[2] G. Powers,et al. Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2 , 1997 .
[3] S. Srinivasula,et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[4] N. Sigal,et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[5] Han van de Waterbeemd,et al. Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..
[6] T. Mitchison,et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL , 2001, Nature Cell Biology.
[7] Kam Y. J. Zhang,et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 , 2001, Nature Cell Biology.
[8] I. Enyedy,et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.
[9] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[10] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[11] Yuzhe Xing,et al. Small Molecule Ligands Define a Binding Site on the Immune Regulatory Protein B7.1* , 2002, The Journal of Biological Chemistry.
[12] J. Kjems,et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[13] A Gene-Expression Inhibitor that Targets an α-Helix-Mediated Protein Interaction , 2003 .
[14] C. Yoakim,et al. Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-Origin DNA complex. , 2003, Bioorganic & medicinal chemistry letters.
[15] A gene-expression inhibitor that targets an alpha-helix-mediated protein interaction. , 2003, Journal of the American Chemical Society.
[16] T. Berg. Modulation of protein-protein interactions with small organic molecules. , 2003, Angewandte Chemie.
[17] Jing Chen,et al. Structure-activity studies of a series of dipyrazolo[3,4-b:3',4'-d]pyridin-3-ones binding to the immune regulatory protein B7.1. , 2003, Bioorganic & medicinal chemistry.
[18] J. Alvarez,et al. Structure-based design of carboxybiphenylindole inhibitors of the ZipA-FtsZ interaction. , 2003, Organic & biomolecular chemistry.
[19] Dajun Yang,et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. , 2004, Journal of medicinal chemistry.
[20] T. Rush,et al. Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction. , 2004, Bioorganic & medicinal chemistry.
[21] Yong Wang,et al. Crystal Structure of the E2 Transactivation Domain of Human Papillomavirus Type 11 Bound to a Protein Interaction Inhibitor* , 2004, Journal of Biological Chemistry.
[22] Alexander D. MacKerell,et al. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. , 2004, Journal of medicinal chemistry.
[23] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[24] Michelle R Arkin,et al. Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. , 2004, Journal of medicinal chemistry.
[25] Frank Petersen,et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .
[26] C. Yoakim,et al. Characterization of the binding site for inhibitors of the HPV11 E1-E2 protein interaction on the E2 transactivation domain by photoaffinity labeling and mass spectrometry. , 2004, Analytical chemistry.
[27] D. Coen,et al. Identification of a small molecule that inhibits herpes simplex virus DNA Polymerase subunit interactions and viral replication. , 2004, Chemistry & biology.
[28] K. Audouze,et al. Emerging classes of protein-protein interaction inhibitors and new tools for their development. , 2004, Current opinion in chemical biology.
[29] Dajun Yang,et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. , 2004 .
[30] Saul H Rosenberg,et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. , 2004, Journal of medicinal chemistry.
[31] Shaomeng Wang,et al. Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2 , 2004, Cancer Research.
[32] Frank Petersen,et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. , 2004, Cancer cell.
[33] P. Fischer. Protein-Protein Interactions in Drug Discovery , 2005 .
[34] J. A. Grant,et al. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.
[35] A. Whitty,et al. Small-molecule inhibition of TNF-alpha. , 2005, Science.
[36] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[37] Jun Wang,et al. Small-Molecule Inhibition of TNF-α , 2005, Science.
[38] J. Mekalanos,et al. Small-Molecule Inhibitor of Vibrio cholerae Virulence and Intestinal Colonization , 2005, Science.
[39] H. Abaan,et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. , 2006, Journal of medicinal chemistry.
[40] Shufeng Zhou,et al. Bioactivation and hepatotoxicity of nitroaromatic drugs. , 2006, Current drug metabolism.
[41] Ramaswamy Nilakantan,et al. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. , 2006, Bioorganic & medicinal chemistry.
[42] Cornel Catana,et al. Inhibition of protein–protein interactions: The discovery of druglike β‐catenin inhibitors by combining virtual and biophysical screening , 2006, Proteins.
[43] Dirk Eick,et al. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. , 2006, Chemistry & biology.
[44] Shaomeng Wang,et al. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. , 2006, Bioorganic & medicinal chemistry letters.
[45] D. Hockenbery,et al. Small-molecule inhibitors of Bcl-2. , 2006, Current opinion in investigational drugs.
[46] P. Fischer. Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53–HDM2 Protein–Protein Interaction , 2006, International Journal of Peptide Research and Therapeutics.
[47] Holger Gohlke,et al. Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. , 2006, Current medicinal chemistry.
[48] Catherine L. Worth,et al. Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.
[49] Sungsam Gong,et al. A Structural Bioinformatics Approach to the Analysis of nonsynonymous Single nucleotide polymorphisms (nsSNPS) and their Relation to Disease , 2007, J. Bioinform. Comput. Biol..
[50] M. Åkesson,et al. Discovery of Selective Small-Molecule CD80 Inhibitors , 2007, Journal of biomolecular screening.
[51] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[52] Sheng Jiang,et al. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. , 2007, Journal of medicinal chemistry.
[53] Mary K Joseph,et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.
[54] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[55] J. Mekalanos,et al. Virstatin inhibits dimerization of the transcriptional activator ToxT , 2007, Proceedings of the National Academy of Sciences.
[56] S. Gellman,et al. Targeting protein-protein interactions: lessons from p53/MDM2. , 2007, Biopolymers.
[57] R. Neubig,et al. Identification of Small-Molecule Inhibitors of RGS4 Using a High-Throughput Flow Cytometry Protein Interaction Assay , 2007, Molecular Pharmacology.
[58] D. Fry. Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. , 2008, Current protein & peptide science.
[59] J. Nör,et al. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Tjelvar S. G. Olsson,et al. The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. , 2008, Journal of molecular biology.
[61] T. Berg. Small-molecule inhibitors of protein-protein interactions. , 2008, Current opinion in drug discovery & development.
[62] J. Walker. Therapeutic Antibodies , 2009, Methods in Molecular Biology™.
[63] György M. Keserü,et al. The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.
[64] Tom Blundell,et al. CREDO: A Protein–Ligand Interaction Database for Drug Discovery , 2009, Chemical biology & drug design.